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The treatment of newborns with safe and effective medicines
is of critical importance for their outcome and subsequent
quality of life. Despite this, it is still a common practice to
prescribe medicines to neonates outside the label, extrapolat-
ing from dosing regimens and indications validated in older
populations and based on non-neonatal pathophysiology. In a
recent meta-analysis (2015) evaluating 829 (1994–2012) stud-
ies on prescribing practices in pediatric hospital care, off-label
and unlicensed medicines prescriptions ranged from 12 to
71 % and 0.2 to 48 %. These authors hereby reconfirmed that
(pre)term neonates were still most commonly exposed to
off-label and unlicensed medicines [12].
The federal US legislation and similar European initiatives
have resulted in a relevant increase in pharmacological studies
in children, with a subsequent significant increase in label
changes. Unfortunately, too few included drug label changes
specific to neonates. To further illustrate this, there were 406
pediatric label changes (Food and Drug Administration,
1997–2010), but only 23 drugs resulted in 11 labeled indica-
tions (e.g., linezolid, rocuronium, remifentanil, sevoflurane,
stavudine, nevirapine) for neonates. The absence of label
change was most commonly because of unproven efficacy,
despite the fact that these compounds (e.g., paracetamol,
caspofungin, valganciclovir) are likely relevant for neonates
[14]. This may largely reflect the difficulties to proof efficacy
due to heterogeneity in patients, variability in outcome vari-
ables, and uncertainty on biomarkers, in addition to demon-
strating safety (risk of adverse drug events) in neonates.
Despite the significant improvements in the knowledge on
pharmacotherapy in older children, neonates still remain
therapeutic orphans [2, 14].
In this issue of the journal, Campino et al. report on the rate
of errors (calculation or accuracy) in intravenous medicine
preparations when performed either bedside in 10 Spanish
neonatal intensive care units (NICUs) or in hospital pharmacy
(HP) services. The study group hereby evaluated the impact of
a structured intervention (protocol standardization, education)
on the number of errors and documented significant improve-
ments in both calculation errors (1.35 to 0 %) and accuracy
(54.7 and 38.3 % to 38.3 and 14.6 % in NICU and HP, respec-
tively) [6]. This intervention paper follows on a previous
paper which described a pre-intervention phase [5] and
illustrates the potential impact of preventive strategies on the
extent of drug errors.
Development of a roadmap to improve neonatal pharma-
ceutical care should aim to improve the knowledge on clinical
pharmacology, clinical pharmacy, and approaches to improve
the knowledge and use of neonatal pharmacovigilance initia-
tives [1]. Another keystone component of such a roadmap
should focus on neonatal drug development, i.e., drug devel-
opment driven by neonatal pathophysiology (Fig. 1).
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Neonatal clinical pharmacology: limited in size,
extensive in variability
The aim of administering a given compound is to reach effec-
tive treatment for a specific disease while avoiding dispropor-
tional side-effects and adverse events. Clinical pharmacology
aims to predict drug-specific (side)-effects based on pharma-
cokinetics (PK) and pharmacodynamics (PD). PK (e.g., ab-
sorption, distribution, and elimination, through either metab-
olism or primary renal elimination) hereby estimates the rela-
tionship between a drug concentration at a specific site (e.g.,
plasma or cerebrospinal fluid) and time (Bwhat the body does
to the drug^). PD describes the concentration effect relation-
ship (Bwhat the drug does to the body^) [1]. Requiring specific
consideration is that these maturational changes in physiology
are most prominent in early infancy and are highly variable
between preterm and term neonates. These maturational phys-
iological trends can be additionally further affected by either
treatment modalities (e.g., whole body cooling, extracorporeal
membrane oxygenation (ECMO), or pharmacotherapy), path-
ophysiological processes or co-morbidities (e.g., perinatal as-
phyxia, sepsis, renal failure, patent ductus arteriosus). All
these changes, both maturational (e.g., age, weight) and path-
ophysiological can result in extensive variability in dosing
within the first days and months of postnatal life [1]. Knowl-
edge integration through utilization of pharmacokinetic
modeling is a method that could improve the current situation.
Such predictive models may convert neonatal pharmacother-
apy from explorative to confirmatory [3, 4, 16].
Neonatal clinical pharmacy: how to cope
with neonatal formulation requirements
The relevance of formulation issues throughout pediatrics,
including neonates has been recently been highlighted, also
in this journal [11, 15]. The administration of drugs via all
routes to neonates poses significant challenges. This is even
more evident for intravenous medicines. These challenges
arise from slow intravenous flow rates, small drug volume,
dead space volume, excipients, and limitations on the flush
volume that can be given in neonates. An appreciation of the
substantial delay and variability in the rate of drug delivery
from the intravenous line is often lacking, but the available
knowledge on this aspect has recently been summarized [13].
Knowledge on neonatal drug delivery has advanced, but there
is still a deficiency of technologies and formulations devel-
oped specifically for this population. As a recent illustration,
we refer to the evaluation of the use of uncoated mini-tablets
instead of syrup for neonates. Uncoated mini-tablets offer the
potential of a single formulation for different age groups and
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Fig. 1 A roadmap to improve
neonatal pharmaceutical care
include improvements in the
fields of clinical pharmacology
[1–4, 16], clinical pharmacy [5, 6,
10, 11, 13, 15], and
pharmacovigilance [7, 8] in
neonates, but should also shift
towards medicines and product
development driven by neonatal
pathophysiology [9]
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avoid the need for specific excipients or taste-masking
compounds [10, 15].
Neonatal pharmacovigilance: how to recognize
the signal in the noise?
Neonatal pharmacovigilance is a powerful tool to improve
healthcare outcomes, but there is an obvious and urgent need
to improve our practices through tailored adverse drug reac-
tion (ADR) reporting, prevention, andmanagement. As it is an
accepted and common practice to prescribe unlicensed and
off-label drugs in neonates, a reasonable and relevant descrip-
tion for an ADR may be Ban unintended, but harmful effect
resulting from the administration to medication(s) intended
for diagnostic or therapeutic reasons.^ Such a definition also
covers medication errors (e.g., wrong dose, wrong route, or
wrong patient) [7]. In addition to the lack of labeling
(e.g., eminence based practices), inappropriate formulations
(e.g., highly concentrated, excipients), (poly)pharmacy
(e.g., maturational drug-drug interactions), immature organ
function (how to discriminate between normal maturational
function and toxicity) and multiple illnesses further increase
the risks for ADRs in neonates.
Pharmacovigilance needs to be adapted to take into consid-
eration the characteristics that are specific to neonates. Such a
strategy should be based on prevention through drug prescrip-
tion and administration errors prevention (e.g., formulation,
bedside manipulation, access) strategies, detection through
laboratory, or clinical outlier data signaling (e.g., reference
laboratory values, overall high morbidity), and subsequent
assessment. Both papers of Campino et al. fit perfectly in such
a preventive strategy [5, 6]. However, once a signal has been
detected, the differentiation of Btrue^ ADRs from confound-
ing events associated with immaturity, organ dysfunction, or
underlying diseases remains difficult. An algorithm as sug-
gested by Du et al. based on 13 questions tailored to neonates
has been shown to be more reliable when compared to the
Naranjo approach [8].
Up to the next level: product development driven
by neonatal pathophysiology
In addition to the above discussed issues, there is also a more
fundamental aspect. At present, almost all compounds admin-
istered or evaluated in neonates were initially developed for
other populations, with subsequent tailoring to the character-
istics of neonates (e.g., formulation, similar or different indi-
cation). A product development plan driven by a newborn-
focused research agenda with specific consideration on their
pathophysiology (e.g., surfactant for hyaline membrane dis-
ease) has the potential to lead to major breakthroughs and
advancements in neonatal pharmaceutical care. Recently, the
International Neonatal Consortium (INC) has been developed
as part of the Critical Path Initiative to serve as a forum for the
neonatal community to develop consensus statements
(e.g., standardization of methods, standard of care consensus
statements, population specific biomarkers, modeling
approaches, trial designs, clinical outcome assessment tools,
formulation issues) with the ultimate goal to improve neonatal
medicines development [9]. This initiative explicitly aims to
accelerate the availability of safe and effective therapies for
neonates. As a first step, a research-focused research agenda
has recently been put forward, to cover prevention and treat-
ment of neonatal brain injury (e.g., neonatal seizures), lung
injury (e.g., bronchopulmonary dysplasia), gastro-intestinal
injury (e.g., necrotizing enterocolitis), neonatal sepsis, reti-
nopathy of prematurity, and neonatal abstinence syndrome
[9]. Although this may look ambitious and strategic, far away
from bedside care, other examples within the Critical Path
Initiative [9] have proven to be very effective to improve
pharmacotherapy for specific disease entities.
In conclusion, improvement in the pharmaceutical care in
neonates is much needed, but possible using the right frame-
works. Knowledge integration and translation to clinical prac-
tice is crucial and must consider clinical pharmacology, clin-
ical pharmacy, or pharmacovigilance (Fig. 1). Similar to both
papers of Campino et al., healthcare providers involved in
neonatal care should be encouraged to consult and assess the
available evidence and subsequently explore effective inter-
ventions. In addition, all stakeholders involved (healthcare
providers, academia, agencies, and sponsors) should consider
to product development driven by a newborn-focused agenda
with emphasis on their pathophysiology. Improved knowl-
edge could and should result in major progresses in neonatal
pharmaceutical care.
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